Sciomics - About Us

The Power of Proteomics: Revolutionizing Science and Healthcare

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. 

At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to improve treatment with Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling.

We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). Our microarray platform, scioDiscover, is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its reliable results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout every stage of your project. Whether you need guidance, have questions, or require full-scale project support, we are committed to ensuring your success: 

Biomarkers_in_Precision_Medicine.jpg

Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. 

Technical Expertise: Our skilled team of professionals provides unmatched proficiency in your proteomic analysis endeavors.

Customized Solutions: We provide customized solutions to meet your specific research needs.  

Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report to provide a complete picture of your medical sample.

 

Our Platform Is Used For:

• Protein Biomarker Identification and Verification

• Novel Drug Target Discovery

• Mode-of-Action Analysis

• Pathway Activity Analysis

• Disease Model Characterization, among other key applications 

 

Join us on our mission to revolutionize medicine. Together, we can reshape the future of healthcare.

News

Article | 3D Bone Marrow Niche Model for Metastatic Neuroblastoma

| September 2026 |A multicellular 3D bone marrow niche engineered on βTCP ceramic scaffolds reproduced key cellular components of the metastatic bone marrow niche in neuroblastoma, with secreted protein profiles and drug responses differing substantially between niches with and without tumour cells. Sciomics supported the study with cytokine and chemokine profiling of human 3D cell culture supernatants using the scioCD® affinity proteomics platform.


Corallo et al., Engineering a multicellular metastatic bone marrow niche using foamed beta tricalcium phosphate scaffolds for advanced neuroblastoma in vitro modeling and drug testing, Next Materials. 2026;13:103575.

 
Collaboration | Multi-tissue proteomics for preclinical safety with FluoSphera

| September 2026 | Some safety questions cannot be answered in a single tissue. When a compound needs hepatic activation before it works, or when a liability only appears where organs influence each other, the model has to contain more than one tissue. Together with FluoSphera SA in Geneva, we offer studies in which tumour and healthy organ tissues are cultured in one well and profiled with scioDiscover® from the same experiment. Phenotypic response and protein signatures are read side by side, so an effect can be traced to a mechanism rather than a dose.


The joint service, the workflow and a proof of concept presented at Swiss Biotech Day 2026 are described at translational-safety.com.

 
Article | Astrocyte Connexin 43 Loss Drives Inflammation and Alpha-Synuclein Pathology in Parkinson’s

| June 2026 | Loss of Connexin 43 gap junctions between astrocytes was linked to increased inflammation and alpha-synuclein aggregation in cell, rat and human Parkinson's models, and pharmacological stabilisation reduced several PD-relevant pathologies in vivo. Sciomics supported the study with cytokine, chemokine and immune-checkpoint profiling of rat CSF using the scioCD affinity proteomics platform.

Hastings et al., Roles of astrocytic Connexin 43 gap junctional deficit in alpha-synucleinopathy and inflammation relevant to Parkinson's, Experimental Neurology. 2026;404:115897.
Article | IVF Stimulation Alters Endometrial Protein Profiles During Implantation

| May 2026 | Significant alterations in endometrial protein expression during ovarian stimulation cycles in women with poor ovarian response suggest potential biomarkers linked to implantation and endometrial receptivity. Sciomics supported the study with protein profiling of human endometrial biopsy tissue usingthe scioDiscover affinity proteomics platform.

Abdulkhalikova et al., Distinct endometrial protein profiles in spontaneous and stimulated cycles in women with poor ovarian response: A prospective case-crossover clinical trial. PLoS One. 2026;21(5):e0338812.  
Article | Stromal Chemokine Rewiring in B Cell Lymphoma

| March 2026 | Inflammatory reprogramming of stromal chemokine networks drives tissue disorganisation and disease progression in nodal B cell lymphoma. Sciomics supported the study with secretome profiling of human iFRC supernatant samples using the scioCD affinity proteomics platform.

Czernilofsky et al., Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma. Nature Cancer. 2026;7:538-552.  

Meet us

BIO-Europe—Cologne (November 9-11, 2026)

Meet our CEO Dr. Christoph Schröder at BIO-Europe 2026 in Cologne. Let's connect!
bioRN Lounge (every last Tuesday of the month)

Want to meet in person? Talk to us at the bioRN Lounge, the regional monthly networking event in Heidelberg taking place every last Tuesday of the month.

Testimonials

PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold

Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, Germany
German Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany

"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."

Product: scioCD

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

BACK_TO_TOP